-
公开(公告)号:US08450317B2
公开(公告)日:2013-05-28
申请号:US12768268
申请日:2010-04-27
申请人: Jennifer A. Kowalski , Daniel Richard Marshall , Anthony S. Prokopowicz, III , Sabine Schlyer , Robert Sibley , Ronald John Sorcek , Di Wu , Frank Wu , Erick Richard Roush Young
发明人: Jennifer A. Kowalski , Daniel Richard Marshall , Anthony S. Prokopowicz, III , Sabine Schlyer , Robert Sibley , Ronald John Sorcek , Di Wu , Frank Wu , Erick Richard Roush Young
IPC分类号: C07D239/34 , C07D239/42 , A61K31/506
CPC分类号: C07D471/04 , C07D209/48 , C07D213/26 , C07D213/56 , C07D213/65 , C07D213/74 , C07D217/00 , C07D231/10 , C07D233/90 , C07D235/04 , C07D239/34 , C07D239/42 , C07D277/30 , C07D295/185 , C07D307/68 , C07D317/68 , C07D319/18 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D413/12 , C07D417/12 , C07D491/08
摘要: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 to R5, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
摘要翻译: 本发明涉及式(I)化合物及其药学上可接受的盐,其中R 1至R 5,A,B,D和X如本文所定义。 本发明还涉及包含这些化合物的药物组合物,使用这些化合物治疗各种疾病和病症的方法,制备这些化合物的方法和可用于这些方法的中间体。
-
2.Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas 审中-公开
标题翻译: 使用芳基和杂芳基取代的杂环脲抑制p38激酶活性公开(公告)号:US20080300281A1
公开(公告)日:2008-12-04
申请号:US12181032
申请日:2008-07-28
申请人: Jacques Dumas , Uday Khire , Timothy B. Lowinger , Bernd Riedl , William J. Scott , Roger A. Smith , Jill E. Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Aniko Redman , Robert Sibley
发明人: Jacques Dumas , Uday Khire , Timothy B. Lowinger , Bernd Riedl , William J. Scott , Roger A. Smith , Jill E. Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Aniko Redman , Robert Sibley
IPC分类号: A61K31/4439 , A61K31/415 , A61K31/4427 , A61K31/381 , A61P19/02
CPC分类号: A61K31/381 , A61K31/415 , A61K31/4427 , A61K31/4439 , Y02A50/411
摘要: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.
摘要翻译: 本发明涉及一组芳基脲在治疗癌症以外的细胞因子介导的疾病和除了癌症以外的蛋白水解酶介导的疾病以及用于这种治疗的药物组合物中的用途。
-
公开(公告)号:US20060108367A1
公开(公告)日:2006-05-25
申请号:US10996502
申请日:2004-11-23
申请人: Robert Sibley
发明人: Robert Sibley
CPC分类号: B65F1/1415 , B65F1/062 , B65F1/1473
摘要: A collection rack comprising a base having a first side and a second side and an integrated waste container dispenser located thereon, a first upright arm extending out from the first side of the base, a second arm extending out from the second side of the base wherein a waste container is attached across the first and second upright arms.
摘要翻译: 收集架,包括具有第一侧和第二侧的基座和位于其上的集成废物容器分配器,从所述基座的第一侧延伸出的第一直立臂,从所述基座的第二侧延伸出的第二臂,其中, 废物容器穿过第一和第二直立臂。
-
4.Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas 失效
标题翻译: 使用喹啉基,异喹啉基或吡啶基脲来抑制RAF激酶公开(公告)号:US20060019990A1
公开(公告)日:2006-01-26
申请号:US11158048
申请日:2005-06-22
申请人: Jacques Dumas , Bernd Riedl , Uday Khire , Robert Sibley , Holia Hatoum-Mokdad , Mary-Katherine Monahan , David Gunn , Timotthy Lowinger , William Scott , Roger Smith , Jill Wood
发明人: Jacques Dumas , Bernd Riedl , Uday Khire , Robert Sibley , Holia Hatoum-Mokdad , Mary-Katherine Monahan , David Gunn , Timotthy Lowinger , William Scott , Roger Smith , Jill Wood
IPC分类号: A61K31/4709 , A61K31/444 , C07D401/02
CPC分类号: C07D213/40
摘要: The invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
摘要翻译: 本发明涉及一组喹啉基,异喹啉基和吡啶基脲,它们在治疗raf介导的疾病中的用途,以及含有用于这种治疗的这些尿素的药物组合物。
-
公开(公告)号:US10450314B2
公开(公告)日:2019-10-22
申请号:US15763690
申请日:2016-09-28
申请人: Boehringer Ingelheim International GmbH , Steven Richard Brunette , Johanna Csengery , Robert Owen Hughes , Xiang Li , Robert Sibley , Michael Robert Turner , Zhaoming Xiong
发明人: Steven Richard Brunette , Johanna Csengery , Robert Owen Hughes , Xiang Li , Robert Sibley , Michael Robert Turner , Zhaoming Xiong
IPC分类号: C07D475/00 , A61K31/519 , C07D475/10
摘要: The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
-
公开(公告)号:US20120165322A1
公开(公告)日:2012-06-28
申请号:US13171696
申请日:2011-06-29
申请人: Brian Nicholas Cook , Jennifer A. Kowalski , Xiang Li , Daniel Richard Marshall , Sabine Schlyer , Robert Sibley , Lana Louise Smith-Keenan , Fariba Soleymanzadeh , Ronald John Sorcek , Erick Richard Roush Young , Yunlong Zhang
发明人: Brian Nicholas Cook , Jennifer A. Kowalski , Xiang Li , Daniel Richard Marshall , Sabine Schlyer , Robert Sibley , Lana Louise Smith-Keenan , Fariba Soleymanzadeh , Ronald John Sorcek , Erick Richard Roush Young , Yunlong Zhang
IPC分类号: A61K31/472 , A61K31/4725 , C07D471/04 , C07D487/04 , A61K31/4985 , C07D417/14 , C07D417/12 , A61K31/5415 , A61K31/541 , C07D413/12 , C07D413/14 , C07D401/12 , A61K31/506 , C07D405/12 , A61K31/5377 , A61K31/538 , A61K31/497 , A61K31/4439 , C07D513/04 , A61K31/428 , A61P9/12 , A61P9/10 , A61P9/00 , A61P25/00 , A61P15/10 , A61P13/12 , A61P11/06 , A61P27/06 , A61P35/00 , A61P25/28 , A61P29/00 , A61P17/06 , A61P1/00 , A61K31/437 , C07D217/02
CPC分类号: C07D217/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04 , C07D519/00
摘要: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
摘要翻译: 本发明涉及式(I)化合物及其药学上可接受的盐,其中R 1和R 2如本文所定义。 本发明还涉及包含这些化合物的药物组合物,使用这些化合物治疗各种疾病和病症的方法,制备这些化合物的方法和可用于这些方法的中间体。
-
7.omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors 有权
标题翻译: ω-羧基芳基取代的二苯脲作为p38激酶抑制剂公开(公告)号:US20080027061A1
公开(公告)日:2008-01-31
申请号:US11845597
申请日:2007-08-27
申请人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , William Scott , Roger Smith , Jill Wood , Mary-Katherine Monahan , Reina Natero , Joel Renick , Robert Sibley
发明人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , William Scott , Roger Smith , Jill Wood , Mary-Katherine Monahan , Reina Natero , Joel Renick , Robert Sibley
IPC分类号: A61K31/535 , A61K31/17 , A61P19/02 , A61K31/495
CPC分类号: A61K31/5377 , A61K31/17 , A61K31/18 , A61K31/24 , A61K31/341 , A61K31/40 , A61K31/4035 , A61K31/44 , A61K31/4439 , A61K31/4453 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5375 , Y02A50/401 , Y02A50/411 , Y02A50/414 , Y02A50/473
摘要: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
摘要翻译: 本发明涉及一组芳基脲在治疗p38介导的疾病中的用途,以及用于此类治疗的药物组合物。
-
8.INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS 失效
标题翻译: 使用ARYL和HETEROARYL取代的杂环类URAAS对RAF激酶的抑制作用公开(公告)号:US20080009527A1
公开(公告)日:2008-01-10
申请号:US11768533
申请日:2007-06-26
申请人: Jacques Dumas , Uday Khire , Timothy Lowinger , Bernard Riedl , William Scott , Roger Smith , Jill Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Aniko Redman , Robert Sibley
发明人: Jacques Dumas , Uday Khire , Timothy Lowinger , Bernard Riedl , William Scott , Roger Smith , Jill Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Aniko Redman , Robert Sibley
IPC分类号: A61K31/4439 , A61K31/415 , A61P35/00 , C07D401/12 , C07D405/04 , C07D231/38 , A61K31/443
CPC分类号: C07D231/40 , C07D333/36 , C07D401/12 , C07D405/04
摘要: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se,
摘要翻译: 用raf激酶介导的肿瘤治疗方法,用取代的脲化合物和这些化合物本身,
-
9.
公开(公告)号:US20070244120A1
公开(公告)日:2007-10-18
申请号:US11768112
申请日:2007-06-25
申请人: Jacques Dumas , Uday Khire , Timothy Lowinger , Holger Paulsen , Bernd Riedl , William Scott , Roger Smith , Jill Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Wendy Lee , Aniko Redman , Robert Sibley , Joel Renick
发明人: Jacques Dumas , Uday Khire , Timothy Lowinger , Holger Paulsen , Bernd Riedl , William Scott , Roger Smith , Jill Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Wendy Lee , Aniko Redman , Robert Sibley , Joel Renick
IPC分类号: A61K31/5377 , A61K31/09 , A61K31/136 , A61K31/381 , A61K31/4164 , A61K31/4196 , A61K31/42 , A61K31/426 , C07D401/12 , C07D231/10 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/4709 , A61K31/496 , A61K31/497
CPC分类号: C07D231/40 , C07D207/34 , C07D259/00 , C07D261/14 , C07D271/113 , C07D285/135 , C07D333/36 , C07D401/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
摘要翻译: 治疗由raf激酶介导的肿瘤与取代的脲化合物及其化合物本身的方法。
-
公开(公告)号:US09403830B2
公开(公告)日:2016-08-02
申请号:US13942988
申请日:2013-07-16
申请人: Asitha Abeywardane , Steven Richard Brunette , Michael Jason Burke , Thomas Martin Kirrane, Jr. , Chuk Chui Man , Daniel Richard Marshall , Anil Kumar Padyana , Hossein Razavi , Robert Sibley , Lana Louise Smith Keenan , Roger John Snow , Ronald John Sorcek , Hidenori Takahashi , Steven John Taylor , Michael Robert Turner , Erick Richard Roush Young , Qiang Zhang , Yunlong Zhang , Renee M. Zindell
发明人: Asitha Abeywardane , Steven Richard Brunette , Michael Jason Burke , Thomas Martin Kirrane, Jr. , Chuk Chui Man , Daniel Richard Marshall , Anil Kumar Padyana , Hossein Razavi , Robert Sibley , Lana Louise Smith Keenan , Roger John Snow , Ronald John Sorcek , Hidenori Takahashi , Steven John Taylor , Michael Robert Turner , Erick Richard Roush Young , Qiang Zhang , Yunlong Zhang , Renee M. Zindell
IPC分类号: C07D487/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D401/04 , C07D401/12 , C07D417/14 , C07D471/04 , C07D471/20 , C07D491/20 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/549 , A61K31/55 , A61K31/551 , C07D405/12 , C07D497/08 , C07D498/04
CPC分类号: C07D487/04 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/549 , A61K31/55 , A61K31/551 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/20 , C07D491/20 , C07D497/08 , C07D498/04
摘要: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein A1, A2, L1 and B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
摘要翻译: 本发明涉及式(I)化合物或其药学上可接受的盐,其中A1,A2,L1和B如本文所定义。 式(I)化合物可用作白三烯A4水解酶(LTA4H)的抑制剂和治疗LTA4H相关病症。 本发明还涉及包含式(I)化合物的药物组合物,使用这些化合物治疗各种疾病和病症的方法,以及制备这些化合物的方法。
-
-
-
-
-
-
-
-
-